Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00025012 · ClinicalTrials.gov registry record · NA

Isotretinoin in Preventing Skin Cancer

A NA study, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

Completed
Registry status
NA
Development phase

NCT00025012: Completed NA study, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

NCT00025012 is a NA study that has completed, run by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00025012, a NA study, has completed, sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

COMPLETED
Registry status
NA
Development phase

Study Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Isotretinoin may be effective in preventing the development or recurrence of skin cancer. PURPOSE: Clinical trial to study the effectiveness of isotretinoin in preventing or slowing the growth of skin cancer in patients who have xeroderma pigmentosum or basal cell carcinoma.

Interventions

  • DRUG isotretinoin

Trial Details

FieldValue
Start Date 1991-06
Est. Completion 2004-02
Phase NA

What the finished NCT00025012 record still lists

NCT00025012 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which isotretinoin is the first listed.

NCT00025012 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00025012 about?

NCT00025012 is a clinical study titled "Isotretinoin in Preventing Skin Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Isotretinoin may be effective in preventing the development or recurrence of skin cancer. PURPOSE: Clinical trial to study the effectiveness of isotretinoin in preventing or slo...

What is the current status of trial NCT00025012?

This trial is currently completed. It is a NA study. The study started on 1991-06. Estimated completion is 2004-02.

What interventions are being tested in trial NCT00025012?

The interventions under investigation include: isotretinoin (DRUG).

Who is sponsoring clinical trial NCT00025012?

This trial is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which has 93 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00025012, the US trial registry maintained by the National Library of Medicine. NCT00025012 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.